{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T18:16:34Z","timestamp":1774548994870,"version":"3.50.1"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"29","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shandong Center for Adverse Drug Reaction Monitoring","award":["No.2021SDADRKY04"],"award-info":[{"award-number":["No.2021SDADRKY04"]}]},{"name":"2021 Shandong Medical Association Clinical Research Fund -- Qilu Special Project","award":["No. YXH2022ZX02059"],"award-info":[{"award-number":["No. YXH2022ZX02059"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,18]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>It has been demonstrated that azole antifungal agents can significantly increase the plasma concentration of dasatinib. Therefore, it is recommended to reduce the dasatinib dose to 20 to 40\u2009mg daily for patients receiving voriconazole. However, the safety of coadministering dasatinib and voriconazole remains unclear.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 49-year-old woman with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia and invasive pulmonary aspergillosis reported dyspnea during therapy with reduced-dose dasatinib and standard-dose voriconazole.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Echocardiography revealed pleural effusion and a mean pulmonary arterial pressure of 40\u2009mm Hg, suggesting pulmonary arterial hypertension.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Dasatinib was discontinued and flumatinib was initiated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient\u2019s mean pulmonary arterial pressure was monitored and gradually normalized.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Despite recommendations to reduce the dasatinib dose to 20 to 40\u2009mg daily for patients on voriconazole, the enhanced effect of dasatinib due to voriconazole coadministration may contribute to the development of pulmonary arterial hypertension. Regular echocardiography follow-up is essential for patients concurrently taking azole antifungal agents.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000042927","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T04:00:13Z","timestamp":1753156813000},"page":"e42927","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Pulmonary arterial hypertension caused by coadministration of dasatinib and voriconazole: A case report and literature review"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0565-0841","authenticated-orcid":false,"given":"Chen","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, The Second Hospital of Shandong University, Jinan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, The Second Hospital of Shandong University, Jinan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningxia","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Hospital of Shandong University, Jinan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, The 960th Hospital of PLA, Jinan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6504-0308","authenticated-orcid":false,"given":"Juandong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The Second Hospital of Shandong University, Jinan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250722","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-319-91439-8_2","article-title":"Dasatinib.","volume":"212","author":"Lindauer","year":"2018","journal-title":"Recent Results Cancer Res"},{"key":"R2-20250722","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1124\/dmd.108.025932","article-title":"Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways.","volume":"37","author":"Li","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"R3-20250722","doi-asserted-by":"crossref","first-page":"797881","DOI":"10.3389\/fphar.2021.797881","article-title":"Therapeutic drug monitoring and individualized medicine of dasatinib: focus on clinical pharmacokinetics and pharmacodynamics.","volume":"12","author":"He","year":"2021","journal-title":"Front Pharmacol"},{"key":"R4-20250722","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.2174\/1389200221666201022140656","article-title":"Differential impacts of azole antifungal drugs on the pharmacokinetic profiles of dasatinib in rats by LC-MS-MS.","volume":"21","author":"Luo","year":"2020","journal-title":"Curr Drug Metab"},{"key":"R5-20250722","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America.","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R6-20250722","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/bloodadvances.2016003889","article-title":"The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia.","volume":"1","author":"Fox","year":"2017","journal-title":"Blood Adv"},{"key":"R7-20250722","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/00015385.2021.1888017","article-title":"Incidence of cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors.","volume":"77","author":"Casavecchia","year":"2022","journal-title":"Acta Cardiol"},{"key":"R8-20250722","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.2169\/internalmedicine.8392-21","article-title":"Relationship between dasatinib-induced pulmonary hypertension and drug dose.","volume":"61","author":"Kubota","year":"2022","journal-title":"Intern Med"},{"key":"R9-20250722","doi-asserted-by":"crossref","first-page":"1802472","DOI":"10.1183\/13993003.02472-2018","article-title":"Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance-pharmacodynamic study.","volume":"53","author":"Cornet","year":"2019","journal-title":"Eur Respir J"},{"key":"R10-20250722","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/bjh.19595","article-title":"Dasatinib induces endothelial dysfunction leading to impaired recovery from ischaemia.","volume":"205","author":"Gover-Proaktor","year":"2024","journal-title":"Br J Haematol"},{"key":"R11-20250722","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/MCP.0000000000000412","article-title":"Pulmonary arterial hypertension induced by tyrosine kinase inhibitors.","volume":"23","author":"Weatherald","year":"2017","journal-title":"Curr Opin Pulm Med"},{"key":"R12-20250722","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1172\/JCI86249","article-title":"Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.","volume":"126","author":"Guignabert","year":"2016","journal-title":"J Clin Invest"},{"key":"R13-20250722","first-page":"1604.e1","article-title":"Dasatinib-induced pulmonary arterial hypertension.","volume":"35","author":"Orlikow","year":"2019","journal-title":"Can J Cardiol"},{"key":"R14-20250722","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/psp4.13146","article-title":"A physiologically-based pharmacokinetic precision dosing approach to manage dasatinib drug-drug interactions.","volume":"13","author":"Kovar","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R15-20250722","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/exd.14038","article-title":"Voriconazole enhances UV-induced DNA damage by inhibiting catalase and promoting oxidative stress.","volume":"29","author":"Lee","year":"2020","journal-title":"Exp Dermatol"},{"key":"R16-20250722","doi-asserted-by":"crossref","first-page":"236","DOI":"10.37201\/req\/013.2023","article-title":"Recommendations on the use of azole antifungals in hematology-oncology patients.","volume":"36","author":"Azanza","year":"2023","journal-title":"Rev Esp Quimioter"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T04:00:15Z","timestamp":1753156815000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":16,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042927","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]}}}